Promising translatable pharmacological interventions for body weight management in individuals with severe mental illness - a narrative review
Research output: Contribution to journal › Review › Research › peer-review
Standard
Promising translatable pharmacological interventions for body weight management in individuals with severe mental illness - a narrative review. / De, Riddhita; Prasad, Femin; Stogios, Nicolette; Burin, Luisa; Ebdrup, Bjørn H; Knop, Filip K; Hahn, Margaret K; Agarwal, Sri Mahavir.
In: Expert Opinion on Pharmacotherapy, Vol. 24, No. 16, 2023, p. 1823-1832.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Promising translatable pharmacological interventions for body weight management in individuals with severe mental illness - a narrative review
AU - De, Riddhita
AU - Prasad, Femin
AU - Stogios, Nicolette
AU - Burin, Luisa
AU - Ebdrup, Bjørn H
AU - Knop, Filip K
AU - Hahn, Margaret K
AU - Agarwal, Sri Mahavir
PY - 2023
Y1 - 2023
N2 - INTRODUCTION: Psychotropic medications, especially antipsychotics, have been consistently shown to cause weight gain in individuals with severe mental illness (SMI), a population inherently challenged by poor physical health. Consequently, compared to the general population, this contributes to an increased cardiometabolic burden, including the risk of type 2 diabetes, dyslipidemia, and hypertension. Furthermore, comorbid obesity leads to treatment nonadherence, decreased quality of life, and increased risk of relapse, posing a challenge in the management of mental health. To address this, emerging agents investigated in the general population with potential to mitigate weight gain were explored to assess translatability to the SMI population.AREAS COVERED: A literature search was conducted including agents approved for the management of obesity in the general population, along with upcoming agents under investigation in phase III trials with weight loss properties.EXPERT OPINION: Metformin and topiramate along with lifestyle interventions are commonly prescribed for weight gain in individuals with SMI; however, their weight loss potential is modest at best. This review identified tirzepatide and cagrilintide-semaglutide among others as promising agents for adjunctive pharmacological management of weight gain.
AB - INTRODUCTION: Psychotropic medications, especially antipsychotics, have been consistently shown to cause weight gain in individuals with severe mental illness (SMI), a population inherently challenged by poor physical health. Consequently, compared to the general population, this contributes to an increased cardiometabolic burden, including the risk of type 2 diabetes, dyslipidemia, and hypertension. Furthermore, comorbid obesity leads to treatment nonadherence, decreased quality of life, and increased risk of relapse, posing a challenge in the management of mental health. To address this, emerging agents investigated in the general population with potential to mitigate weight gain were explored to assess translatability to the SMI population.AREAS COVERED: A literature search was conducted including agents approved for the management of obesity in the general population, along with upcoming agents under investigation in phase III trials with weight loss properties.EXPERT OPINION: Metformin and topiramate along with lifestyle interventions are commonly prescribed for weight gain in individuals with SMI; however, their weight loss potential is modest at best. This review identified tirzepatide and cagrilintide-semaglutide among others as promising agents for adjunctive pharmacological management of weight gain.
KW - Humans
KW - Diabetes Mellitus, Type 2/drug therapy
KW - Quality of Life
KW - Mental Disorders/drug therapy
KW - Obesity/drug therapy
KW - Weight Gain
KW - Antipsychotic Agents/therapeutic use
KW - Weight Loss
U2 - 10.1080/14656566.2023.2254698
DO - 10.1080/14656566.2023.2254698
M3 - Review
C2 - 37653675
VL - 24
SP - 1823
EP - 1832
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
SN - 1465-6566
IS - 16
ER -
ID: 387696222